Selling, General, and Administrative Costs: Walgreens Boots Alliance, Inc. vs Iovance Biotherapeutics, Inc.

A Tale of Two Companies: Walgreens Boots Alliance vs. Iovance Biotherapeutics

In the ever-evolving landscape of corporate finance, the Selling, General, and Administrative (SG&A) expenses serve as a critical indicator of a company's operational efficiency. Over the past decade, Walgreens Boots Alliance, Inc. has consistently demonstrated robust SG&A management, with expenses hovering around $23 billion annually. This stability reflects the company's strategic focus on cost control amidst a competitive retail environment.

Conversely, Iovance Biotherapeutics, Inc., a burgeoning player in the biotech sector, has seen its SG&A expenses grow exponentially, from approximately $9 million in 2014 to over $106 million in 2023. This 1,000% increase underscores the company's aggressive investment in research and development, a hallmark of its growth strategy.

While Walgreens' expenses peaked in 2024, Iovance's data for that year remains elusive, leaving room for speculation on its future trajectory. This comparison highlights the diverse financial strategies employed by companies in different sectors.